Sunovion has announced the US launch of Seebri Neohaler glycopyrrolate DPI for the treatment of COPD. Seebri Neohaler was approved by the FDA in October 2015.
Seebri Neohaler is known as Seebri Breezhaler outside of the US. Arcapta Neohaler and Utibron Neohaler are known as Onbrez Breezhaler and Ultibro Breezhaler in other parts of the world.
Sunovion Executive VP and Chief Commercial Officer David Frawley commented, “As a part of our commitment to millions of people living with COPD in the United States, Sunovion is pleased to introduce Seebri Neohaler as a new treatment option. Seebri Neohaler, a handheld, dry powder inhaler, is an important part of Sunovion’s COPD portfolio that includes a broad range of medications and delivery methods that can address individual patient needs.”
Read the Sunovion press release.
